S2k guideline on diagnosis and treatment of atopic dermatitis--short version.

Atopic dermatitis (AD) represents a pruritic, non-contagious, chronic or chronically relapsing, inflammatory skin disease. The course of the disease may be complicated by bacterial or viral superinfections. The first manifestation of the disease and further flare-ups are due to genetic predisposition and also to a variety of further trigger factors. The therapy regimen should be adapted to disease symptoms that are actually present and consider individual features of the disease as reported by the patients or their parents. This short version of the German guideline on AD provides an overview of evidence-based diagnostic and treatment options. All recommendations made here are the result of a consensus of the scientific medical societies, working groups and support groups based on scientific data published to date. Abstracts and details of the studies cited are provided in the long version of this guideline (see: www.awmf.org).

Werfel T ，Heratizadeh A ，Aberer W ，Ahrens F ，Augustin M ，Biedermann T ，Diepgen T ，Fölster-Holst R ，Gieler U ，Kahle J ，Kapp A ，Nast A ，Nemat K ，Ott H ，Przybilla B ，Roecken M ，Schlaeger M ，Schmid-Grendelmeier P ，Schmitt J ，Schwennesen T ，Staab D ，Worm M ... -  《-》

S2k guideline on diagnosis and treatment of atopic dermatitis - short version.

Werfel T ，Heratizadeh A ，Aberer W ，Ahrens F ，Augustin M ，Biedermann T ，Diepgen T ，Fölster-Holst R ，Gieler U ，Kahle J ，Kapp A ，Nast A ，Nemat K ，Ott H ，Przybilla B ，Roecken M ，Schlaeger M ，Schmid-Grendelmeier P ，Schmitt J ，Schwennesen T ，Staab D ，Worm M ... -  《-》

Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis].

Werfel T ，Aberer W ，Ahrens F ，Augustin M ，Biedermann T ，Diepgen T ，Fölster-Holst R ，Gieler U ，Heratizadeh A ，Kahle J ，Kapp A ，Nast A ，Nemat K ，Ott H ，Przybilla B ，Roecken M ，Schlaeger M ，Schmid-Grendelmeier P ，Schmitt J ，Schwennesen T ，Staab D ，Worm M ，Association of Scientific Medical Societies of Germany ... -  《-》

Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians.

An effective treatment strategy for chronic pruritus in children with dermatologic disorders should consider the multidimensional aspects of pruritus, the unique challenges associated with treating pruritic skin disorders in the pediatric population, and evidence-based therapies with demonstrated antipruritic benefits and clinically relevant effects on patient/family quality of life (QoL). The Course of Advanced Learning for the Management of ITch (CALM-IT) Task Force is an interdisciplinary group of experts specializing in core aspects of pruritus treatment, integrating pediatrics, dermatology, psychotherapy, pruritus management, and sleep. CALM-IT recently convened to provide updated guidance on managing chronic pruritus associated with dermatologic diseases in pediatric patients, with a special focus on atopic dermatitis (AD) and chronic spontaneous urticaria (csU). This review highlights the updated concepts and best practices, which were built upon international PRACTALL consensus and modified for children and infants with AD and csU. CALM-IT supports the routine use of basic skin therapy and the escalation of topical medications, according to severity and focused on rapid itch control. Anti-inflammatory agents should be appropriate for infants and children (i.e., with an optimized therapeutic index) and have proven antipruritic properties, such as those demonstrated by methylprednisolone aceponate. New experimental findings do not support the use of non-sedating oral antihistamines as adjuvant antipruritic therapy for AD. In csU, oral H1 -antihistamine use is justified, consistent with the distinct pathophysiologic mechanisms of itch underlying AD and csU. All encompassing QoL assessments should consider the burden of both patient and caregiver and should address outstanding unmet clinical needs of pediatric patients. Future research areas include integrated QoL assessments and multidisciplinary treatment programs with pediatric-targeted pruritic therapies providing rapid itch control.

Metz M ，Wahn U ，Gieler U ，Stock P ，Schmitt J ，Blume-Peytavi U ... -  《-》

American Academy of Dermatology Guidelines for Managing Atopic Dermatitis.

The American Academy of Dermatology first published a series of guidelines for diagnosing and managing atopic dermatitis in 2014. Twelve clinicians were selected to review, grade, and offer clinical insight on available data regarding the clinical features, symptomology, pathophysiology, education, treatment, and emerging clinical studies on atopic dermatitis (AD). Based on these findings, the AAD released a guideline to streamline information on atopic dermatitis for physicians, recommending using clinical evidence to diagnose and first treating with nonpharmacologic therapies to restore the natural skin barrier. Topical pharmacologic therapies were recommended for improving pruritus and inflammation and newer systemic agents for clinically relevant moderate-to-severe cases. Evidence-based practices were emphasized in comparison to those that lacked therapeutic data. To highlight the emerging evidence and pharmacologic breakthroughs in atopic dermatitis, the AAD produced an updated set of guidelines educating physicians on new agents and their role in treatment. This chapter reviews the AAD guidelines as a tool for managing atopic dermatitis and staying up to date on disease advancements.

Robinson L ，Strowd LC 《Advances in Experimental Medicine and Biology》